Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.42 |
| ▸ | NPC1 | O15118 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CRACR2A | Q9BSW2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21189268 | 1.00 | RAB9A (0.42) | RAB9ANPC1SMN1; SMN2TP53MAOB | |
| SCHEMBL21189258 | 0.92 | SMN1; SMN2 (0.40) | RAB9ANPC1SMN1; SMN2TP53MAOB | |
| SCHEMBL21189535 | 0.91 | MEN1 (0.44) | RAB9ANPC1SMN1; SMN2TP53LMNA | |
| SCHEMBL21189257 | 0.91 | MEN1 (0.44) | RAB9ANPC1SMN1; SMN2TP53LMNA | |
| SCHEMBL19973519 | 0.89 | RAB9A (0.45) | RAB9ANPC1SMN1; SMN2TP53MAOB | |
| SCHEMBL19974011 | 0.89 | RAB9A (0.45) | RAB9ANPC1SMN1; SMN2TP53MAOB | |
| SCHEMBL21189206 | 0.88 | TP53 (0.42) | RAB9ANPC1SMN1; SMN2TP53MAOB | |
| SCHEMBL21189262 | 0.88 | TP53 (0.42) | RAB9ANPC1SMN1; SMN2TP53MAOB | |
| SCHEMBL21189485 | 0.88 | TP53 (0.42) | RAB9ANPC1SMN1; SMN2TP53MAOB | |
| SCHEMBL19973496 | 0.88 | RAB9A (0.42) | RAB9ANPC1SMN1; SMN2TP53MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-05-11 | — | — | US | disclosed |
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | CBX8, HAVCR2, HCCS | RAB9A 1393/4885NPC1 983/4885SMN1; SMN2 3837/4885 |
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | CBX8, HAVCR2, HCCS | RAB9A 1393/4885NPC1 983/4885SMN1; SMN2 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.